Nervous system diseases

NHS England to trial inclusion of depression in new medicine service

David Webb, chief pharmaceutical officer for England, told the 2022 Clinical Pharmacy Congress that the pilot was "just the tip of the iceberg in terms of opportunity" for pharmacy.…

Epilepsy: management

An overview of commonly used anti-seizure medicines as well as guidance on their initiation, adding on and withdrawal.…

Epilepsy: symptoms and diagnosis

An overview of epilepsy, including seizure types, associated risks and diagnosis.…

Antidepressants do not improve quality of life long term, study finds

After two years of follow up, researchers found no statistical difference in health-related quality of life scores in those who took antidepressants compared with those who did not.…

A digital approach to improving valproate safety

The development of a virtual dashboard in Surrey has made it possible to identify women taking valproate who are approaching their annual review and highlight those who may need to see their GP.…

More than 1,000 patients stopped taking antidepressants after introduction of local deprescribing guidelines

Exclusive: Guidelines published in 2021 have helped Sunderland Clinical Commissioning Group move from having the fifth highest antidepressant prescribing rate in the country to the eighth highest.…

Multiple sclerosis: disease-modifying therapies

An overview of the available evidence for each disease-modifying therapy for multiple sclerosis, when they are indicated, as well as each stage of patient care.…

Therapy combined with MDMA is effective in treating severe PTSD, phase III trial results suggest

Researchers concluded that MDMA-assisted therapy was highly efficacious, safe and well tolerated in those suffering from severe post-traumatic stress disorder.…

Boots to provide mental health care service for £65 per month

The service has been launched in response to a rise in patients asking for mental health advice and support in Boots pharmacies.…

Combined treatment with mirtazapine linked to better outcomes in patients with acute depression, review shows

Combining a reuptake inhibitor with a presynaptic α2-autoreceptor antagonist was found to be the most effective combination in terms of treatment outcomes.…